Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights
Provided By PR Newswire
Last update: Aug 14, 2025
- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) -
- Cash, cash equivalents, and marketable securities of $296.3 million at Q2 2025; runway through at least 2027 -
Read more at prnewswire.com
